The effect of the levonorgestrel-releasing intrauterine system, Mirena® on mast cell numbers in women with endometriosis undergoing symptomatic treatment
article
OA: closed
CC0
⤵ 7 in-corpus citations
Limited metadata. Only one source feed has indexed
this record so far — no abstract, full text, or open-access copy is
available through Endo Lab. The
publisher's page (linked below)
is the canonical location for the actual content. If you have institutional
access, use "Find at my library".
AI-generated summary
This study investigated the impact of the levonorgestrel-releasing intrauterine system (Mirena®) on mast cell counts in women with endometriosis experiencing symptomatic relief.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
My notes (saved in your browser only)
Condition tags
MeSH descriptors
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
References (25)
- Changes in glandular and stromal estrogen and progesterone receptor isoform expression in eutopic and ectopic endometrium following treatment with the levonorgestrel-releasing intrauterine system via openalex
- Cyclooxygenase-2 expression in deep endometriosis and matched eutopic endometrium via openalex
- Cytokine profiles in serum and peritoneal fluid from infertile women with and without endometriosis via openalex
- EPIDEMIOLOGY OF ENDOMETRIOSIS via openalex
- Epigallocatechin-3-gallate inhibits estrogen-induced activation of endometrial cells in vitro and causes regression of endometriotic lesions in vivo via openalex
- Immunobiology of endometriosis via openalex
- Increased Mast Cell Density in Peritoneal Endometriosis Compared with Eutopic Endometrium with Endometriosis via openalex
- Increase of Activated Mast Cells in Human Endometriosis via openalex
- Peritoneal Vascular Density Assessment Using Narrow-Band Imaging and Vascular Analysis Software, and Cytokine Analysis in Women With and Without Endometriosis via openalex
- Stem Cell Factor (SCF) Concentrations in Peritoneal Fluid of Women with or without Endometriosis via openalex
- The efficacy, side-effects and continuation rates in women with symptomatic endometriosis undergoing treatment with an intra-uterine administered progestogen (levonorgestrel): a 3 year follow-up via openalex
- The evaluation of the effectiveness of an intrauterine-administered progestogen (levonorgestrel) in the symptomatic treatment of endometriosis and in the staging of the disease via openalex
- Treating endometriosis as an autoimmune disease via openalex
- W2115835613 via openalex
- W2010606095 via openalex
- W2123134517 via openalex
- W2141369001 via openalex
- W2053998452 via openalex
- W2053305404 via openalex
- W2042810511 via openalex
- W2038480158 via openalex
- W2033247060 via openalex
- W2170487877 via openalex
- W2345696364 via openalex
- W2468902048 via openalex
Cited by (7)
- Clinical practice guidelines for endometriosis in Japan (The 3rd edition) 2022
- Modern menstruation: Is it abnormal and unhealthy? 2020
- Hormonal contraception in women with endometriosis: a systematic review 2019
- Targeting mast cells: a new way to treat endometriosis 2016
- [Sodium cromoglycate attenuates experimental endometriosis in rats by regulating mast cells]. 2015
- Curbing Inflammation in Multiple Sclerosis and Endometriosis: Should Mast Cells Be Targeted? 2015
- Stretch magnitude- and frequency-dependent cyclooxygenase 2 and prostaglandin E2 up-regulation in human endometrial stromal cells: Possible implications in endometriosis 2012
Source provenance
- europepmc
- last seen: 2026-06-04T01:30:01.192114+00:00
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
- pubmed
- last seen: 2026-05-13T22:16:29.858026+00:00
License: CC0
· commercial use OK